New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma

Cancer

Volumn 118, Issue 6, 2012, Pages 1486-1497

  Agulnik, Mark ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

everolimus; mammalian target of rapamycin (mTOR) protein; ridaforolimus; sarcoma; sirolimus; temsirolimus

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VATALANIB; VINCRISTINE;

ABNORMAL LABORATORY RESULT; ADVANCED CANCER; ANEMIA; ANGIOMYOLIPOMA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APHTHOUS ULCER; ASTHENIA; BLADDER CARCINOMA; BREAST TUMOR; CANCER INHIBITION; CANCER SURVIVAL; COLORECTAL TUMOR; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; EWING SARCOMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEMANGIOENDOTHELIOMA; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER TUMOR; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MACULOPAPULAR RASH; MAINTENANCE CHEMOTHERAPY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYELONEPHRITIS; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; RESPIRATORY TRACT INFECTION; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DISEASE; SKIN TOXICITY; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEIN KINASE INHIBITORS; SARCOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84055206678     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26361     Document Type: Review

References (107)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™: Soft Tissue Sarcoma, Version 1.2011. Accessed February 8, 2011.
2. Surveillance Epidemiology and End Results Program. SEER Stat Fact Sheet: Soft Tissue Including Heart. Accessed November 22, 2010.
3. Surveillance Epidemiology and End Results Program. SEER Stat Fact Sheet: Bone and Joint. Accessed November 22, 2010.
4. Mahalingam D, Mita A, Sankhala K, et al. Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets. 2009; 10: 937-949.
5. Fasolo A, Sessa C,. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs. 2008; 17: 1717-1734.
6. Goberdhan DC, Boyd CA,. mTOR: dissecting regulation and mechanism of action to understand human disease. Biochem Soc Trans. 2009; 37 (pt 1): 213-216.
7. Jiang BH, Liu LZ,. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat. 2008; 11: 63-76.
8. Figlin RA, Brown E, Armstrong AJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008; 6 (suppl 5): S1-S20; quiz S21-S22.
9. Faivre S, Kroemer G, Raymond E,. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5: 671-688. (Pubitemid 44151605)
10. Dancey JE,. Therapeutic targets: mTOR and related pathways. Cancer Biol Ther. 2006; 5: 1065-1073. (Pubitemid 44773684)
11. Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM,. Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol. 2009; 5: 291-303.
12. Wan X, Helman LJ,. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007; 12: 1007-1018. (Pubitemid 47359144)
13. Menon S, Manning BD,. Common corruption of the mTOR signaling network in human tumors. Oncogene. 2008; 27 (suppl 2): S43-S51.
14. Memmott RM, Dennis PA,. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009; 21: 656-664.
15. Averous J, Proud CG,. When translation meets transformation: the mTOR story. Oncogene. 2006; 25: 6423-6435. (Pubitemid 44582286)
16. Hay N, Sonenberg N,. Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926-1945. (Pubitemid 39071573)
17. Bjornsti MA, Houghton PJ,. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4: 335-348. (Pubitemid 38579480)
18. Ma XM, Blenis J,. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009; 10: 307-318.
19. Semenza GL,. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-732. (Pubitemid 37328811)
20. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B,. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002; 2: 826-835. (Pubitemid 37328901)
21. Hsieh AC, Moasser MM,. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007; 97: 453-457. (Pubitemid 47258458)
22. Yuan R, Kay A, Berg WJ, Lebwohl D,. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy [serial online]. J Hematol Oncol. 2009; 2: 45.
23. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM,. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008; 14: 6364-6370.
24. Samani AA, Yakar S, LeRoith D, Brodt P,. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007; 28: 20-47. (Pubitemid 46220849)
25. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O,. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res. 1999; 59: 3588-3591. (Pubitemid 29381857)
26. Girnita L, Girnita A, Wang M, Meis-Kindblom JM, Kindblom LG, Larsson O,. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. Oncogene. 2000; 19: 4298-4301.
27. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT,. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004; 64: 2047-2053. (Pubitemid 38339452)
28. Ganti R, Skapek SX, Zhang J, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol. 2006; 19: 1213-1220. (Pubitemid 44268191)
29. Sampson JR,. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans. 2009; 37 (pt 1): 259-264.
30. Umeoka S, Koyama T, Miki Y, Akai M, Tsutsui K, Togashi K,. Pictorial review of tuberous sclerosis in various organs [serial online]. Radiographics. 2008; 28: e32.
31. Boyd KP, Korf BR, Theos A,. Neurofibromatosis type 1. J Am Acad Dermatol. 2009; 61: 1-14; quiz 15-16.
32. Katz D, Lazar A, Lev D,. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 2009; 11: e30.
33. Kapoor A, Figlin RA,. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer. 2009; 115: 3618-3630.
34. Ritacco FV, Graziani EI, Summers MY, et al. Production of novel rapamycin analogs by precursor-directed biosynthesis. Appl Environ Microbiol. 2005; 71: 1971-1976. (Pubitemid 40546120)
35. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001; 7: 1758-1764. (Pubitemid 32708646)
36. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M,. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol. 2004; 15: 1510-1516. (Pubitemid 39409742)
37. Kirchner GI, Meier-Wiedenbach I, Manns MP,. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004; 43: 83-95. (Pubitemid 38283132)
38. Pfizer. TORISEL (temsirolimus) prescribing information. New York: Pfizer; 2008.
39. Novartis Pharmaceuticals Corporation. Afinitor (everolimus) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.
40. Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F,. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs. 2008; 17: 1947-1954.
41. Busca R, Bertolotto C, Ortonne JP, Ballotti R,. Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem. 1996; 271: 31824-31830. (Pubitemid 26422202)
42. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T,. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 1999; 59: 3581-3587. (Pubitemid 29381856)
43. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008; 50: 799-805. (Pubitemid 351354788)
44. Houghton PJ, Morton CL, Gorlick R, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther. 2010; 9: 101-112.
45. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ,. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006; 8: 394-401. (Pubitemid 43830746)
46. Mitsiades N, McMullan C, Poulaki V, et al. The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo [abstract]. Blood (ASH Annual Meeting Abstracts). 2004; 104: 418a. Abstract 1496.
47. Johnson BE, Jackman D, Janne PA,. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed nonsmall cell lung cancer. Clin Cancer Res. 2007; 13 (15 pt 2): s4628-s4631.
48. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008; 135: 1972-1983.
49. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007; 67: 2408-2413. (Pubitemid 46548923)
50. O'Reilly T, Vaxelaire J, Muller M,. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models [abstract]. Proc Am Assoc Cancer Res. 2002; 43. Abstract 359.
51. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004; 64: 252-261. (Pubitemid 38114106)
52. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003; 75: 1710-1717. (Pubitemid 36629155)
53. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005; 11: 5319-5328. (Pubitemid 41003721)
54. Rossi F, Ehlers I, Agosti V, et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A. 2006; 103: 12843-12848. (Pubitemid 44298649)
55. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007; 13: 748-753. (Pubitemid 46889749)
56. Clackson T, Metcalf CA, Rivera VM, et al. Broad anti-tumor activity of ap23573, an mTOR inhibitor in clinical development [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 882.
57. Squillace R, Miller D, Clapham D, et al. Anti-tumor activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in sarcoma and endometrial cancer models and exploration of molecular correlates of sensitivity [abstract 1482]. Paper presented at: 99th Annual Meeting of the American Association for Cancer Research; April 12-16, 2008; San Diego, Calif.
58. Squillace R, Miller D, Clackson T, Rivera V,. Anti-proliferative activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in combination with cytotoxic and targeted agents in sarcoma and endometrial cancer models [abstract 4006]. Paper presented at: 99th Annual Meeting of the American Association for Cancer Research; April 12-16, 2008; San Diego, Calif.
59. Jimeno A, Rudek MA, Kulesza P, et al. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008; 26: 4172-4179.
60. AIDS Malignancy Clinical Trials Consortium. Sirolimus in treating patients with HIV-related Kaposi's sarcoma. ClinicalTrials.gov: NCT00450320. Accessed February 9, 2011.
61. Cohen EE, Sharma M, Janisch LA, et al. A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies [abstract]. J Clin Oncol. 2010; 28 (15S). Abstract 2591.
62. Cirstea D, Hideshima T, Rodig S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010; 9: 963-975.
63. Abraxis BioScience, LLC. ABI-009 trial in patients with advanced non-hematologic malignancies. ClinicalTrials.gov: NCT00635284. Accessed February 18, 2011.
64. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res. 2006; 12: 5755-5763. (Pubitemid 44629606)
65. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004; 22: 2336-2347. (Pubitemid 41115390)
66. Buckner JC, Forouzesh B, Erlichman C, et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs. 2010; 28: 334-342.
67. Cancer Therapy and Research Center, Texas. Sorafenib and temsirolimus in treating patients with unresectable or metastatic solid tumors. ClinicalTrials.gov: NCT00 255658. Accessed May 13, 2011.
68. University of North Carolina Lineberger Comprehensive Center. Temsirolimus and valproic acid in treating young patients with relapsed neuroblastoma, bone sarcoma, or soft tissue sarcoma. ClinicalTrials.gov: NCT01204450. Accessed February 18, 2011.
69. University of Southern California/Norris Comprehensive Cancer Center. Temsirolimus and vinorelbine ditartrate in treating patients with unresectable or metastatic solid tumors. ClinicalTrials.gov: NCT01155258. Accessed February 18, 2011.
70. Sidney Kimmel Comprehensive Cancer Center. Safety and efficacy study of torisel and liposomal doxorubicin for patients with recurrent sarcoma. ClinicalTrials.gov: NCT00949325. Accessed February 18, 2011.
71. New Mexico Cancer Care Alliance. Phase I/II study of irinotecan and temsirolimus in patients with refractory sarcomas. ClinicalTrials.gov: NCT00996346. Accessed February 18, 2011.
72. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1603-1610.
73. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1588-1595.
74. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ,. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007; 26: 611-621. (Pubitemid 350115107)
75. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol. 2007; 25: 4806-4812. (Pubitemid 350086485)
76. Hospital Santa Marcelina. Phase II study of everolimus in children and adolescents with refractory or relapsed rhabdomyosarcoma and other soft tissue sarcomas. ClinicalTrials.gov: NCT01216839. Accessed February 18, 2011.
77. St. Jude Children's Research Hospital. Everolimus for treating pediatric patients with recurrent or refractory tumors. ClinicalTrials.gov: NCT00187174. Accessed February 18, 2011.
78. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008; 26: 361-367. (Pubitemid 351171685)
79. Hartford CM, Desai AA, Janisch L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009; 15: 1428-1434.
80. Mita MM, Britten CD, Poplin E, et al. Deforolimus trial 106-a phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669) [abstract]. J Clin Oncol. 2008; 26 (15S). Abstract 3509.
81. Gore L, Trippett TM, Katzenstein HM, et al. A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors [abstract]. J Clin Oncol. 2010; 28 (15S). Abstract 9531.
82. Sessa C, Tosi D, Vigano L, et al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol. 2009; 21: 1315-1322.
83. Merck. Trial of deforolimus in combination with bevacizumab for patients with advanced cancers. ClinicalTrials.gov: NCT00781846. Accessed May 24, 2010.
84. The University of Texas Health Science Center at San Antonio. Study of oral ridaforolimus in combination with standard chemotherapy for soft tissue sarcoma. ClinicalTrials.gov: NCT01296659. Accessed February 18, 2011.
85. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 140-151.
86. Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo Phase 2 Consortium (P2C) [published online ahead of print February 1, 2011]. Cancer. 2011.
87. Schoffski P, Reichardt P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010; 21: 1990-1998.
88. Chawla SP, Staddon AP, Baker LH, et al. A phase 2 study of the mTOR inhibitor ridaforolimus (AP23573; MK 8669) in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. In press.
89. Chawla SP, Blay J, Ray-Coquard IL, et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT) [abstract]. J Clin Oncol. 2011; 29S. Abstract 10005.
90. Children's Hospital Medical Center, Cincinnati. Safety and efficacy study of sirolimus in complicated vascular anomalies. ClinicalTrials.gov: NCT00975819. Accessed February 18, 2011.
91. University of Michigan Cancer Center. A phase II study of oral cyclophosphamide and sirolimus (OCR) in advanced sarcoma. ClinicalTrials.gov: NCT00743509. Accessed February 9, 2011.
92. Geoerger B, Kieran MW, Grupp S, et al. Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma [abstract]. J Clin Oncol. 2010; 28 (15S). Abstract 9541.
93. Beckman Research Institute. MEK inhibitor AZD6244 with or without temsirolimus in treating patients with metastatic, recurrent, or locally advanced soft tissue sarcoma that cannot be removed by surgery. ClinicalTrials.gov: NCT01206140. Accessed February 18, 2011.
94. Albert Einstein College of Medicine of Yeshiva University. Temsirolimus in treating patients with recurrent or persistent cancer of the uterus. ClinicalTrials.gov: NCT01061606. Accessed February 18, 2011.
95. Children's Oncology Group. Vinorelbine ditartrate and cyclophosphamide in combination with bevacizumab or temsirolimus in treating patients with recurrent or refractory rhabdomyosarcoma. ClinicalTrials.gov: NCT01222715. Accessed February 18, 2011.
96. Richter S, Pink D, Hohenberger P, et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST [abstract]. J Clin Oncol. 2010; 28 (15S). Abstract 10038.
97. Novartis Pharmaceuticals. Treatment of patients with RAD001 who have progressive sarcoma. ClinicalTrials.gov: NCT00767819. Accessed February 18, 2011.
98. Dana-Farber Cancer Institute. RAD001 in combination with CP-751,871 in patients with advanced sarcomas and other malignant neoplasms. ClinicalTrials.gov: NCT00927966. Accessed February 18, 2011.
99. Novartis Pharmaceuticals. Treatment of patients with everolimus and imatinib mesylate who have progressive gastrointestinal stromal tumors (GIST) and are resistant to imatinib mesylate. ClinicalTrials.gov: NCT00510354. Accessed February 18, 2011.
100. Merck. Phase II study of MK8669 with metastatic bone or soft-tissue sarcoma patients (8669-030). ClinicalTrials.gov: NCT01010672. Accessed February 18, 2011.
101. Merck. Ridaforolimus in treatment of sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus). ClinicalTrials.gov: NCT00 538239. Accessed April 21, 2010.
102. Sonis S, Treister N, Chawla S, Demetri G, Haluska F,. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010; 116: 210-215.
103. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011; 17: 871-879.
104. Merck. A combination study with ridaforolimus (MK8669) and dalotuzumab (MK0646) in patients with advanced cancer. ClinicalTrials.gov: NCT00730379. Accessed May 24, 2010.
105. Memorial Sloan-Kettering Cancer Center. Temsirolimus and cixutumumab in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma. ClinicalTrials.gov: NCT01016015. Accessed February 9, 2011.
106. Naing A, LoRusso P, Gupta S, et al. Dual inhibition of IGFR and mTOR pathways [abstract]. J Clin Oncol. 2010; 28 (15S). Abstract 3007.
107. Manara MC, Nicoletti G, Zambelli D, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res. 2010; 16: 530-540.